Patient characteristics
| Cohort n=147 | ANA+JIA, n=58 (40%) | ANA−JIA, n=24 (16%) | Idiopathic uveitis, n=36 (25%) | ERA, n=9 (6%) | Sarcoidosis, n=9 (6%) | Others uveitis, n=11 (7%) | |
| Age at inflammatory disease diagnostic (years) Mean±SD (n–N) | 6.5±4 (1.5–17) | 4±3 (1–13) | 4.4±2 (1.5–10) | 9.1±4.2 (1–17) | 11±4.1 (3–16) | 7.7±4.8 (5–12) | 9.9±4.8 (2.5–15) |
| Age at uveitis diagnostic (years) | 7.4±4.2 (1.5–17) | 5±3 (1.5–15) | 6±2.5 (3–13) | 9.1±4.2 (1–17) | 11.8±4.2 (4–16) | 10.5±2.4 (7–14) | 10.9±4.4 (2–17) |
| Sex, n (%) Female | 107 (74) | 51 (87) | 22 (91) | 17 (48) | 5 (55) | 5 (55) | 7 (63) |
| Follow-up (months) | 52±37.8 (3–168) | 62.5±39 (3–168) | 56±40.5 (3–156) | 40±32 (6–168) | 28±25.5 (3–84) | 52±27.6 (20–84) | 43±40 (5–132) |
| Laboratory analysis, n (%) | |||||||
| ANA | 76 (52) | 58 | 0 | 14 (39) | 2 (22) | 0 | 2 (18) |
| HLA B27 | 12 (8) | 1 | 2 | 0 | 9 | 0 | 0 |
| High ACE | 9 (6) | 0 | 0 | 0 | 0 | 9 | 0 |
| ESR, mean±SD (n – N) | 24±26.6 (1–120) | 36.4±33 (1–120) | 21±20 (1–63) | 14.4±17 (1–65) | 13±8 (1–28) | 12±14 (2–40) | – |
| CRP mean±SD (n – N) | 14.5±26 (1–197) | 16±23.8 (1–197) | 22±32 (4–100) | 5±5.5 (5–9) | 14±25 (5–78) | 5±4.6 (1–15) | – |
| Uveitis location, n (%) | |||||||
| Anterior | 137 (93) | 58 | 24 | 32 (94) | 9 | 7 (77) | 9 (81) |
| Intermediate | 2 (1) | 0 | 0 | 1 (3) | 0 | 0 | 0 |
| Posterior | 1 | 0 | 0 | 0 | 0 | 0 | 1 (10) |
| Panuveitis | 7 (6) | 0 | 0 | 3 (8) | 0 | 2 (23) | 2 (18) |
| Unilateral, n (%) Bilateral, n (%) | 36 (21) 116 (79) | 8 (14) 50 (86) | 6 (25) 18 (75) | 10 (27) 26 (73) | 7 (77) 2 (23) | 0 9 (100) | 2 (18) 9 (82) |
| Granulomatous uveitis, n (%) | 18 (12) | 2 (3) | 4 (16) | 9 (31) | 0 | 2 (23) | 1 (10) |
| Signs at onset, n (%) | |||||||
| Synechiae | 40 (27) | 16 (27) | 11 (45) | 8 (22) | 0 | 3 (33) | 2 (18) |
| Vision loss | 40 (27) | 10 (17) | 7 (30) | 12 (33) | 1 (11) | 4 (44) | 6 (54) |
| SUN classification, cells, at diagnostic, n (%) | |||||||
| SUN 0.5+ | 22 (15) | 14 (25) | 3 (12) | 3 (8) | 1 (11) | 0 | 1 (10) |
| SUN 1+ | 50 (34) | 13 (23) | 12 (50) | 16 (45) | 5 (55) | 2 (22) | 2 (18) |
| SUN 2+ | 60 (41) | 24 (42) | 9 (38) | 15 (41) | 2 (22) | 6 (66) | 4 (36) |
| SUN 3+ | 15 (10) | 6 (10) | 1 (4) | 2 (5) | 1 (11) | 1 (11) | 4 (36) |
ANA, antinuclear antibody; CRP, C reactive protein; ERA, enthesitis-related arthritis ; ESR, erythrocyte sedimentation rate; JIA, juvenile idiopathic arthritis; SUN, Standardization of Uveitis Nomenclature.